|
US3906092A
(en)
|
1971-11-26 |
1975-09-16 |
Merck & Co Inc |
Stimulation of antibody response
|
|
US4415732A
(en)
|
1981-03-27 |
1983-11-15 |
University Patents, Inc. |
Phosphoramidite compounds and processes
|
|
US4373071A
(en)
|
1981-04-30 |
1983-02-08 |
City Of Hope Research Institute |
Solid-phase synthesis of polynucleotides
|
|
US4401796A
(en)
|
1981-04-30 |
1983-08-30 |
City Of Hope Research Institute |
Solid-phase synthesis of polynucleotides
|
|
DE3314999A1
(en)
|
1983-04-26 |
1985-03-14 |
Behringwerke Ag, 3550 Marburg |
USE OF THE DITERPEN DERIVATE FORSKOLIN FOR IMMUNE STIMULATION
|
|
US5663163A
(en)
|
1987-09-07 |
1997-09-02 |
Fujisawa Pharmaceutical Co., Ltd. |
Cephem compounds and processes for preparation thereof
|
|
CA1320446C
(en)
|
1988-06-20 |
1993-07-20 |
William A. Carter |
Modulation of lymphokine-resistant cellular states by dsrnas
|
|
JP3150967B2
(en)
|
1989-10-11 |
2001-03-26 |
エイチイーエム リサーチ，インコーポレイティド |
Protection from shock following double-stranded RNA damage
|
|
ATE138384T1
(en)
|
1993-01-25 |
1996-06-15 |
Hybridon Inc |
OLIONUCLEOTIDE ALKYLPHOSPHONATE AND PHOSPHONOTHIOATE
|
|
JPH08510720A
(en)
|
1993-01-27 |
1996-11-12 |
アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ |
Compositions and methods for transdermal drug delivery
|
|
US5516652A
(en)
|
1993-10-06 |
1996-05-14 |
Merck Frosst Canada Inc. |
DNA encoding prostaglandin receptor IP
|
|
US5965720A
(en)
|
1994-03-18 |
1999-10-12 |
Lynx Therapeutics, Inc. |
Oligonucleotide N3'→P5' phosphoramidates
|
|
WO1995026204A1
(en)
|
1994-03-25 |
1995-10-05 |
Isis Pharmaceuticals, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
|
US5874560A
(en)
|
1994-04-22 |
1999-02-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Melanoma antigens and their use in diagnostic and therapeutic methods
|
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
JP3468773B2
(en)
|
1994-07-15 |
2003-11-17 |
ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション |
Immunomodulatory oligonucleotide
|
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US7148205B2
(en)
|
1995-12-13 |
2006-12-12 |
Mirus Bio Corporation |
Intravascular delivery of non-viral nucleic acid
|
|
US6689757B1
(en)
|
1996-02-12 |
2004-02-10 |
M.L. Laboratories Plc |
Methods for vaccination and vaccines therefor
|
|
US6090391A
(en)
|
1996-02-23 |
2000-07-18 |
Aviron |
Recombinant tryptophan mutants of influenza
|
|
AU3799797A
(en)
*
|
1996-07-15 |
1998-02-09 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
|
|
US6610661B1
(en)
|
1996-10-11 |
2003-08-26 |
The Regents Of The University Of California |
Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
|
|
EP0839912A1
(en)
|
1996-10-30 |
1998-05-06 |
Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) |
Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
|
|
GB9623051D0
(en)
|
1996-11-06 |
1997-01-08 |
Schacht Etienne H |
Delivery of DNA to target cells in biological systems
|
|
EP0855184A1
(en)
|
1997-01-23 |
1998-07-29 |
Grayson B. Dr. Lipford |
Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
|
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
|
WO1998047913A2
(en)
|
1997-04-18 |
1998-10-29 |
The University Of Medicine And Dentistry Of New Jersey |
Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
|
|
EP1374894A3
(en)
|
1997-06-06 |
2004-09-22 |
Dynavax Technologies Corporation |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
|
CA2293489C
(en)
|
1997-06-06 |
2009-09-29 |
The Regents Of The University Of California |
Inhibitors of dna immunostimulatory sequence activity
|
|
US6589940B1
(en)
|
1997-06-06 |
2003-07-08 |
Dynavax Technologies Corporation |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
|
US20040006034A1
(en)
|
1998-06-05 |
2004-01-08 |
Eyal Raz |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
|
EP1872786A1
(en)
|
1997-09-05 |
2008-01-02 |
The Regents of the University of California |
Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
|
|
US6096307A
(en)
|
1997-12-11 |
2000-08-01 |
A. Glenn Braswell |
Compositions for immunostimulation containing Echinacea angustofolia, bromelain, and lysozyme
|
|
WO1999051259A2
(en)
|
1998-04-03 |
1999-10-14 |
University Of Iowa Research Foundation |
Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
|
|
AU3758199A
(en)
|
1998-04-23 |
1999-11-08 |
Regents Of The University Of Michigan, The |
Peptides for efficient gene transfer
|
|
EP1196558A1
(en)
|
1999-06-08 |
2002-04-17 |
Aventis Pasteur |
Immunostimulant oligonucleotide
|
|
CA2312385A1
(en)
|
1999-06-22 |
2000-12-22 |
Daiso Co., Ltd. |
Process for producing erythro-3-amino-2-hydroxybutyric acid derivatives
|
|
US6514948B1
(en)
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
|
WO2001004135A2
(en)
|
1999-07-13 |
2001-01-18 |
The Regents Of The University Of Michigan |
Crosslinked dna condensate compositions and gene delivery methods
|
|
US20030104622A1
(en)
|
1999-09-01 |
2003-06-05 |
Robbins Paul D. |
Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
|
|
ES2238799T3
(en)
|
1999-09-09 |
2005-09-01 |
Curevac Gmbh |
RNA-M TRANSFER.
|
|
AT409085B
(en)
|
2000-01-28 |
2002-05-27 |
Cistem Biotechnologies Gmbh |
PHARMACEUTICAL COMPOSITION FOR IMMUNULATING AND PRODUCING VACCINES
|
|
WO2001055341A2
(en)
|
2000-01-31 |
2001-08-02 |
The Regents Of The University Of California |
Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
|
|
NZ522045A
(en)
|
2000-03-30 |
2007-05-31 |
Whitehead Biomedical Inst |
RNA sequence-specific mediators of RNA interference
|
|
EP1292331A2
(en)
|
2000-06-07 |
2003-03-19 |
Biosynexus Incorporated |
Immunostimulatory rna/dna hybrid molecules
|
|
SI1296714T1
(en)
|
2000-06-22 |
2010-01-29 |
S For Entpr University Of Iowa |
Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
|
|
DK1292615T3
(en)
|
2000-06-23 |
2007-02-19 |
Wyeth Corp |
Modified morbillivirus V proteins
|
|
US6376704B1
(en)
|
2000-06-28 |
2002-04-23 |
3M Innovative Properties Company |
Naphthyoxyalkyl(meth)acrylates with high refractive indices and low glass transition temperatures
|
|
US6716434B1
(en)
|
2000-09-19 |
2004-04-06 |
Daniel R. Ansley |
Composition and method for immunostimulation in non- mammalian vertebrates
|
|
GB0025577D0
(en)
|
2000-10-18 |
2000-12-06 |
Smithkline Beecham Biolog |
Vaccine
|
|
US7371387B2
(en)
|
2001-02-21 |
2008-05-13 |
Genitrix Llc |
Vaccine compositions and methods of modulating immune responses
|
|
US7704963B2
(en)
|
2001-04-02 |
2010-04-27 |
University Of South Florida |
LPS-responsive chs1/beige-like anchor gene and therapeutic applications thereof
|
|
EP1383556B9
(en)
|
2001-04-21 |
2008-03-19 |
Curevac GmbH |
INJECTION DEVICE FOR ADMINISTERING mRNA
|
|
ES2340499T3
(en)
|
2001-06-05 |
2010-06-04 |
Curevac Gmbh |
TUMOR ANTIGEN ARNM STABILIZED WITH AN INCREASED G / C CONTENT.
|
|
US7785610B2
(en)
|
2001-06-21 |
2010-08-31 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—III
|
|
IL159334A0
(en)
|
2001-06-25 |
2004-06-01 |
Yissum Res Dev Co |
A method for preparation of vesicles loaded with biological material and different uses thereof
|
|
AR045702A1
(en)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
COMPOSITIONS OF ASSISTANTS.
|
|
DE10148886A1
(en)
|
2001-10-04 |
2003-04-30 |
Avontec Gmbh |
Inhibition of STAT-1
|
|
WO2003035836A2
(en)
|
2001-10-24 |
2003-05-01 |
Hybridon Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
|
|
US7276489B2
(en)
|
2002-10-24 |
2007-10-02 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
|
|
DE10162480A1
(en)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
The application of mRNA for use as a therapeutic agent against tumor diseases
|
|
WO2003059381A2
(en)
|
2002-01-18 |
2003-07-24 |
Curevac Gmbh |
Immunogenic preparations and vaccines on the basis of mrna
|
|
WO2003066649A1
(en)
|
2002-02-04 |
2003-08-14 |
Biomira Inc. |
Immunostimulatory, covalently lipidated oligonucleotides
|
|
CA2476182A1
(en)
|
2002-03-01 |
2003-09-12 |
The Administrators Of The Tulane Educational Fund |
Conjugates of therapeutic or cytotoxic agents and biologically active peptides
|
|
ES2734652T3
(en)
|
2002-04-04 |
2019-12-11 |
Zoetis Belgium S A |
Immunostimulatory oligonucleotides containing G and U
|
|
US20060188990A1
(en)
|
2002-04-19 |
2006-08-24 |
Schering Aktiengesellschaft |
Novel prostate tumor-specific promoter
|
|
DE10229872A1
(en)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immune stimulation through chemically modified RNA
|
|
EP1393745A1
(en)
|
2002-07-29 |
2004-03-03 |
Hybridon, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends
|
|
WO2004058159A2
(en)
|
2002-12-23 |
2004-07-15 |
Dynavax Technologies Corporation |
Branched immunomodulatory compounds and methods of using the same
|
|
KR101123489B1
(en)
|
2003-01-16 |
2012-03-28 |
이데라 파마슈티칼즈, 인코포레이티드 |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
|
|
US9068234B2
(en)
*
|
2003-01-21 |
2015-06-30 |
Ptc Therapeutics, Inc. |
Methods and agents for screening for compounds capable of modulating gene expression
|
|
US8969543B2
(en)
|
2003-04-03 |
2015-03-03 |
Bioneer Corporation |
SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
|
|
US20040242502A1
(en)
|
2003-04-08 |
2004-12-02 |
Galenica Pharmaceuticals, Inc. |
Semi-synthetic saponin analogs with carrier and immune stimulatory activities for DNA and RNA vaccines
|
|
AU2004252409A1
(en)
|
2003-04-10 |
2005-01-06 |
3M Innovative Properties Company |
Methods and compositions for enhancing immune response
|
|
JP4887143B2
(en)
|
2003-06-30 |
2012-02-29 |
ユニベルシテ ド ローザンヌ |
RasGAP-derived peptide that selectively kills cancer cells
|
|
WO2005004907A1
(en)
|
2003-07-10 |
2005-01-20 |
Cytos Biotechnology Ag |
Packaged virus-like particles
|
|
CN1829794B
(en)
|
2003-08-05 |
2011-06-08 |
Avi生物制药公司 |
Oligonucleotide analog and method for treating flavivirus infections
|
|
DE10335833A1
(en)
|
2003-08-05 |
2005-03-03 |
Curevac Gmbh |
Transfection of blood cells with mRNA for immune stimulation and gene therapy
|
|
GB0321615D0
(en)
|
2003-09-15 |
2003-10-15 |
Glaxo Group Ltd |
Improvements in vaccination
|
|
EP1663316A2
(en)
|
2003-09-25 |
2006-06-07 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid lipophilic conjugates
|
|
DE10346721A1
(en)
|
2003-10-08 |
2005-05-04 |
Holger Kalthoff |
New oligonucleotides, useful for treating cancer, especially of the pancreas, are not species specific but induce apoptosis or inhibit proliferation
|
|
WO2005035549A2
(en)
|
2003-10-14 |
2005-04-21 |
Kernel Biopharma Inc. |
Amiphiphylic peptide-pna conjugates for the delivery of pna through the blood brain barrier
|
|
US20050112139A1
(en)
|
2003-10-23 |
2005-05-26 |
Nmk Research, Llc |
Immunogenic composition and method of developing a vaccine based on factor H binding sites
|
|
US20050215501A1
(en)
|
2003-10-24 |
2005-09-29 |
Coley Pharmaceutical Group, Inc. |
Methods and products for enhancing epitope spreading
|
|
EP1699814A4
(en)
|
2003-12-08 |
2009-01-14 |
Hybridon Inc |
Modulation of immunostimulatory properties by small oligonucleotide-based compounds
|
|
WO2005062947A2
(en)
|
2003-12-22 |
2005-07-14 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for identifying rna-binding proteins
|
|
WO2005097993A2
(en)
|
2004-02-19 |
2005-10-20 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory viral rna oligonucleotides
|
|
AU2005326144A1
(en)
|
2004-06-08 |
2006-08-03 |
Coley Pharmaceutical Gmbh |
Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
|
|
WO2006046978A2
(en)
|
2004-06-28 |
2006-05-04 |
Argos Therapeutics, Inc. |
Cationic peptide-mediated transformation
|
|
DE102004035227A1
(en)
|
2004-07-21 |
2006-02-16 |
Curevac Gmbh |
mRNA mixture for vaccination against tumor diseases
|
|
WO2006015789A2
(en)
*
|
2004-08-03 |
2006-02-16 |
Geneart Ag |
Method for modulating gene expression by modifying the cpg content
|
|
DE102004042546A1
(en)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Combination therapy for immune stimulation
|
|
WO2006029223A2
(en)
|
2004-09-08 |
2006-03-16 |
Children's Medical Center Corporation |
Method for stimulating the immune response of newborns
|
|
TW200636064A
(en)
*
|
2004-10-28 |
2006-10-16 |
Centocor Inc |
Anti-respiratory syncytial virus antibodies, antigens and uses thereof
|
|
PL1830888T3
(en)
|
2004-12-27 |
2015-12-31 |
Silence Therapeutics Gmbh |
Lipid complexes coated with peg and their use
|
|
EP1874348A4
(en)
|
2005-04-14 |
2009-10-28 |
Univ Queensland |
IMMUNOMODULATING COMPOSITIONS AND THEIR USES
|
|
WO2006116458A2
(en)
|
2005-04-26 |
2006-11-02 |
Coley Pharmaceutical Gmbh |
Modified oligoribonucleotide analogs with enhances immunostimulatory activity
|
|
DE102005023170A1
(en)
|
2005-05-19 |
2006-11-23 |
Curevac Gmbh |
Optimized formulation for mRNA
|
|
JP5329949B2
(en)
|
2005-05-31 |
2013-10-30 |
エコーレ ポリテクニーク フェデラーレ デ ローザンヌ |
Triblock copolymers for cytoplasmic delivery of gene-based drugs
|
|
EP1924284A1
(en)
|
2005-09-14 |
2008-05-28 |
Hartmann, Gunther |
Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
|
|
EP1764107A1
(en)
|
2005-09-14 |
2007-03-21 |
Gunther Hartmann |
Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
|
|
JP2009511034A
(en)
|
2005-10-12 |
2009-03-19 |
キャンサー・リサーチ・テクノロジー・リミテッド |
Methods and compositions for treating immune disorders
|
|
CN101346393B
(en)
|
2005-11-02 |
2015-07-22 |
普洛体维生物治疗公司 |
Modified siRNA molecules and uses thereof
|
|
US7470674B2
(en)
|
2005-11-07 |
2008-12-30 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
|
|
KR20080072934A
(en)
|
2005-11-25 |
2008-08-07 |
콜리 파마슈티칼 게엠베하 |
Immunostimulatory oligoribonucleotides
|
|
US9687262B2
(en)
|
2005-11-30 |
2017-06-27 |
CARDINAL HEALTH SWITZERLAND 515 GmbH |
Methods and devices for treating vulnerable plaque
|
|
JP2009519033A
(en)
|
2005-12-16 |
2009-05-14 |
ディアト |
Cell penetrating peptide conjugates for delivering nucleic acids to cells
|
|
WO2007120368A2
(en)
|
2006-01-09 |
2007-10-25 |
The Regents Of The University Of California |
Immunostimulatory combinations for vaccine adjuvants
|
|
DE102006007433A1
(en)
|
2006-02-17 |
2007-08-23 |
Curevac Gmbh |
Adjuvant in the form of a lipid-modified nucleic acid
|
|
WO2007124755A1
(en)
|
2006-05-02 |
2007-11-08 |
The Antibody Project Aps |
Method for immunizing an avian species
|
|
DE102006035618A1
(en)
|
2006-07-31 |
2008-02-07 |
Curevac Gmbh |
Nucleic acid of the formula (I): GlXmGn, in particular as immunostimulating adjuvant
|
|
EP2046954A2
(en)
|
2006-07-31 |
2009-04-15 |
Curevac GmbH |
NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
|
|
US20080076701A1
(en)
|
2006-08-18 |
2008-03-27 |
Nastech Pharmaceutical Company Inc. |
Dicer substrate rna peptide conjugates and methods for rna therapeutics
|
|
EP1911844A1
(en)
|
2006-10-10 |
2008-04-16 |
Qiagen GmbH |
Methods and kit for isolating nucleic acids
|
|
DE102006051516A1
(en)
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Base) modified RNA to increase the expression of a protein
|
|
DE102006061015A1
(en)
|
2006-12-22 |
2008-06-26 |
Curevac Gmbh |
Process for the purification of RNA on a preparative scale by HPLC
|
|
DE102007001370A1
(en)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-encoded antibodies
|
|
JP2010535248A
(en)
|
2007-07-31 |
2010-11-18 |
ザ ジョンズ ホプキンス ユニバーシティー |
Polypeptide-nucleic acid complex for immunological prevention or immunotherapy of neoplastic disorders or infections
|
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
|
WO2009046739A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
|
WO2009053700A1
(en)
|
2007-10-23 |
2009-04-30 |
Cancer Research Technology Limited |
Modification of nucleic acid-containing biological entities
|
|
US20110038888A1
(en)
|
2008-01-10 |
2011-02-17 |
Peter Emtage |
Adjuvant compositions comprising poly-ic and a cationic polymer
|
|
KR101483715B1
(en)
|
2008-01-31 |
2015-01-19 |
큐어백 게엠바하 |
NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS/ADJUVANTS
|
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
|
WO2009144230A1
(en)
|
2008-05-26 |
2009-12-03 |
Universität Zürich |
Protamine/rna nanoparticles for immunostimulation
|
|
EP2328919A2
(en)
|
2008-08-25 |
2011-06-08 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
|
WO2010067041A1
(en)
|
2008-12-11 |
2010-06-17 |
Hybrid Biosystems Limited |
Modification of nucleic acid vectors with polymers comprising charged quaternary amino groups
|
|
WO2010088927A1
(en)
|
2009-02-09 |
2010-08-12 |
Curevac Gmbh |
Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
|
|
EP2456470A1
(en)
|
2009-07-22 |
2012-05-30 |
Cenix Bioscience GmbH |
Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
|
|
WO2011011631A2
(en)
|
2009-07-22 |
2011-01-27 |
Samuel Zalipsky |
Nucleic acid delivery vehicles
|
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
|
WO2011069528A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Lyophilization of nucleic acids in lactate-containing solutions
|
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
|
EP2387999A1
(en)
|
2010-05-21 |
2011-11-23 |
CureVac GmbH |
Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
|
|
US20130121998A1
(en)
|
2010-06-16 |
2013-05-16 |
Myra A. Lipes |
Diagnosis of Myocardial Autoimmunity in Heart Disease
|
|
ES2558106T3
(en)
|
2010-07-30 |
2016-02-02 |
Curevac Ag |
Formation of nucleic acid complexes with disulfide-cross-linked cationic components for transfection and immunostimulation
|
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
WO2012024629A1
(en)
|
2010-08-20 |
2012-02-23 |
Selecta Biosciences, Inc. |
Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin
|
|
US9511135B2
(en)
*
|
2010-09-14 |
2016-12-06 |
Stc.Unm |
Immunogenic respiratory syncytial virus glycoprotein-containing VLPs and related compositions, constructs, and therapeutic methods
|
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
|
WO2012116714A1
(en)
*
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
AU2012255971A1
(en)
|
2011-05-13 |
2013-05-02 |
Novartis Ag |
Pre-fusion RSV F antigens
|
|
US9763891B2
(en)
|
2011-07-22 |
2017-09-19 |
The General Hospital Corporation |
Therapeutic nanoparticles and methods of use thereof
|
|
EP2623121A1
(en)
|
2012-01-31 |
2013-08-07 |
Bayer Innovation GmbH |
Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
|
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
ES2660129T3
(en)
|
2012-03-27 |
2018-03-20 |
Curevac Ag |
Artificial nucleic acid molecules comprising a 5'UTR-TOP
|
|
CA2866955A1
(en)
|
2012-03-27 |
2013-10-03 |
Curevac Gmbh |
Artificial nucleic acid molecules
|
|
MX362981B
(en)
|
2012-03-27 |
2019-02-28 |
Curevac Ag |
Artificial nucleic acid molecules for improved protein or peptide expression.
|
|
EP3498267A1
(en)
|
2012-05-25 |
2019-06-19 |
CureVac AG |
Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
|
|
MX385338B
(en)
|
2013-02-22 |
2025-03-18 |
CureVac SE |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
WO2014160463A1
(en)
|
2013-03-13 |
2014-10-02 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Prefusion rsv f proteins and their use
|
|
AU2014310930A1
(en)
|
2013-08-21 |
2016-01-21 |
Curevac Ag |
Composition and vaccine for treating prostate cancer
|
|
SG11201510748PA
(en)
|
2013-08-21 |
2016-03-30 |
Curevac Ag |
Composition and vaccine for treating lung cancer
|
|
CN105473157A
(en)
|
2013-08-21 |
2016-04-06 |
库瑞瓦格股份公司 |
Combination vaccine
|
|
SG11201510746WA
(en)
|
2013-08-21 |
2016-03-30 |
Curevac Ag |
Respiratory syncytial virus (rsv) vaccine
|
|
CN105451779A
(en)
|
2013-08-21 |
2016-03-30 |
库瑞瓦格股份公司 |
Method for increasing expression of RNA-encoded proteins
|
|
CN105517569A
(en)
|
2013-08-21 |
2016-04-20 |
库瑞瓦格股份公司 |
Rabies vaccine
|
|
WO2015062738A1
(en)
|
2013-11-01 |
2015-05-07 |
Curevac Gmbh |
Modified rna with decreased immunostimulatory properties
|
|
US11254951B2
(en)
|
2014-12-30 |
2022-02-22 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
KR102399799B1
(en)
|
2013-12-30 |
2022-05-18 |
큐어백 아게 |
Artificial nucleic acid molecules
|
|
AU2014375404C1
(en)
|
2013-12-30 |
2020-11-19 |
CureVac Manufacturing GmbH |
Methods for RNA analysis
|
|
CA2927254C
(en)
|
2013-12-30 |
2023-10-24 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
ES2754239T3
(en)
|
2014-03-12 |
2020-04-16 |
Curevac Ag |
Combination of vaccination and OX40 agonists
|
|
US10369216B2
(en)
|
2014-04-01 |
2019-08-06 |
Curevac Ag |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
|
MX382298B
(en)
|
2014-06-10 |
2025-03-12 |
Curevac Mfg Gmbh |
METHODS AND MEANS FOR INCREASING RNA PRODUCTION.
|
|
DE202015009961U1
(en)
|
2014-12-12 |
2022-01-25 |
Curevac Ag |
Artificial nucleic acid molecules for improved protein expression
|
|
CA2962849A1
(en)
|
2014-12-16 |
2016-06-23 |
Curevac Ag |
Ebolavirus and marburgvirus vaccines
|
|
CA2966092A1
(en)
|
2014-12-30 |
2016-07-07 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
EP4353257A3
(en)
|
2015-04-13 |
2024-08-07 |
CureVac Manufacturing GmbH |
Method for producing rna compositions
|
|
CN107567497A
(en)
|
2015-04-17 |
2018-01-09 |
库瑞瓦格股份公司 |
Lyophilization of RNA
|
|
US10293058B2
(en)
|
2015-04-22 |
2019-05-21 |
Curevac Ag |
RNA containing composition for treatment of tumor diseases
|
|
SG11201708681SA
(en)
|
2015-04-30 |
2017-11-29 |
Curevac Ag |
Method for in vitro transcription using an immobilized restriction enzyme
|
|
EP3289101B1
(en)
|
2015-04-30 |
2021-06-23 |
CureVac AG |
Immobilized poly(n)polymerase
|
|
WO2016180430A1
(en)
|
2015-05-08 |
2016-11-17 |
Curevac Ag |
Method for producing rna
|
|
KR20180004820A
(en)
|
2015-05-15 |
2018-01-12 |
큐어백 아게 |
A novel prime-boost therapy comprising administration of at least one mRNA construct
|
|
WO2016184576A2
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
EP3916091A3
(en)
|
2015-05-20 |
2022-03-30 |
CureVac AG |
Dry powder composition comprising long-chain rna
|
|
EP3303575B1
(en)
|
2015-05-29 |
2022-03-16 |
CureVac AG |
Method for adding cap structures to rna using immobilized enzymes
|
|
ES2960429T3
(en)
|
2015-05-29 |
2024-03-04 |
Curevac Mfg Gmbh |
Method for producing and purifying RNA, comprising at least one tangential flow filtration step
|
|
US20180296663A1
(en)
|
2015-06-17 |
2018-10-18 |
Curevac Ag |
Vaccine composition
|
|
EP4239080A3
(en)
|
2015-07-01 |
2023-11-01 |
CureVac Manufacturing GmbH |
Method for analysis of an rna molecule
|
|
US10501768B2
(en)
|
2015-07-13 |
2019-12-10 |
Curevac Ag |
Method of producing RNA from circular DNA and corresponding template DNA
|
|
WO2017021546A1
(en)
|
2015-08-05 |
2017-02-09 |
Curevac Ag |
Epidermal mrna vaccine
|
|
WO2017025120A1
(en)
|
2015-08-07 |
2017-02-16 |
Curevac Ag |
Process for the in vivo production of rna in a host cell
|
|
EP3825407A1
(en)
|
2015-08-10 |
2021-05-26 |
CureVac Real Estate GmbH |
Method of increasing the replication of a circular dna molecule
|
|
AU2016316439B2
(en)
|
2015-08-28 |
2022-02-24 |
CureVac SE |
Artificial nucleic acid molecules
|
|
EP3362576A1
(en)
|
2015-10-12 |
2018-08-22 |
CureVac AG |
Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
|
|
MX2018004917A
(en)
|
2015-10-22 |
2019-04-01 |
Modernatx Inc |
Respiratory syncytial virus vaccine.
|
|
US20180312545A1
(en)
|
2015-11-09 |
2018-11-01 |
Curevac Ag |
Optimized nucleic acid molecules
|
|
EP3373965A1
(en)
|
2015-11-09 |
2018-09-19 |
CureVac AG |
Rotavirus vaccines
|
|
WO2017108087A1
(en)
|
2015-12-21 |
2017-06-29 |
Curevac Ag |
Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
|
|
AU2016375021B2
(en)
|
2015-12-22 |
2022-02-03 |
CureVac SE |
Method for producing RNA molecule compositions
|
|
WO2017109161A1
(en)
|
2015-12-23 |
2017-06-29 |
Curevac Ag |
Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
|
WO2017137095A1
(en)
|
2016-02-12 |
2017-08-17 |
Curevac Ag |
Method for analyzing rna
|
|
EP3417069A1
(en)
|
2016-02-15 |
2018-12-26 |
CureVac AG |
Method for analyzing by-products of rna in vitro transcription
|
|
US11723967B2
(en)
|
2016-02-17 |
2023-08-15 |
CureVac SE |
Zika virus vaccine
|
|
EP3423595A1
(en)
|
2016-03-03 |
2019-01-09 |
CureVac AG |
Rna analysis by total hydrolysis
|
|
EP3433361A1
(en)
|
2016-03-24 |
2019-01-30 |
CureVac AG |
Immobilized inorganic pyrophosphatase (ppase)
|
|
CA3015570A1
(en)
|
2016-03-29 |
2017-10-05 |
Peter Kwong |
Substitutions-modified prefusion rsv f proteins and their use
|
|
US20190343942A1
(en)
|
2016-04-22 |
2019-11-14 |
Curevac Ag |
Rna encoding a tumor antigen
|
|
WO2017186928A1
(en)
|
2016-04-29 |
2017-11-02 |
Curevac Ag |
Rna encoding an antibody
|
|
US20180126003A1
(en)
|
2016-05-04 |
2018-05-10 |
Curevac Ag |
New targets for rna therapeutics
|
|
EP4233898A3
(en)
|
2016-05-04 |
2023-11-01 |
CureVac SE |
Influenza mrna vaccines
|
|
EP3452101A2
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Rna encoding a therapeutic protein
|
|
EP4477662A3
(en)
|
2016-05-04 |
2025-03-19 |
CureVac SE |
Nucleic acid molecules and uses thereof
|
|
EP3464619A1
(en)
|
2016-05-25 |
2019-04-10 |
CureVac AG |
Novel biomarkers
|
|
US20190336611A1
(en)
|
2016-06-09 |
2019-11-07 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
|
WO2017212008A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
|
EP3468609A1
(en)
|
2016-06-09 |
2019-04-17 |
CureVac AG |
Cationic carriers for nucleic acid delivery
|
|
US11478552B2
(en)
|
2016-06-09 |
2022-10-25 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
|
BR112019000598A2
(en)
|
2016-08-19 |
2019-07-02 |
Curevac Ag |
rna for cancer therapy
|
|
KR20190093816A
(en)
|
2016-10-26 |
2019-08-26 |
큐어백 아게 |
Lipid nanoparticle mRNA vaccine
|
|
WO2018096179A1
(en)
|
2016-11-28 |
2018-05-31 |
Curevac Ag |
Method for purifying rna
|
|
US11464836B2
(en)
|
2016-12-08 |
2022-10-11 |
Curevac Ag |
RNA for treatment or prophylaxis of a liver disease
|
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
|
US11141476B2
(en)
|
2016-12-23 |
2021-10-12 |
Curevac Ag |
MERS coronavirus vaccine
|
|
WO2018115525A1
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Lassa virus vaccine
|
|
US11524066B2
(en)
|
2016-12-23 |
2022-12-13 |
CureVac SE |
Henipavirus vaccine
|
|
EP3595713A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
RESPIRATORY SYNCYTIAL VIRUS VACCINE
|
|
EP3595715A1
(en)
|
2017-03-17 |
2020-01-22 |
CureVac AG |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
|
EP3601576A1
(en)
|
2017-03-24 |
2020-02-05 |
CureVac AG |
Nucleic acids encoding crispr-associated proteins and uses thereof
|
|
EP3424524B1
(en)
|
2017-07-04 |
2024-12-11 |
CureVac SE |
Cancer rna-vaccine
|
|
WO2019038332A1
(en)
|
2017-08-22 |
2019-02-28 |
Curevac Ag |
Bunyavirales vaccine
|
|
RU2020117848A
(en)
|
2017-11-08 |
2021-12-08 |
Куревак Аг |
PHK SEQUENCE ADAPTATION
|
|
EP3723796A1
(en)
|
2017-12-13 |
2020-10-21 |
CureVac AG |
Flavivirus vaccine
|
|
SG11202005760PA
(en)
|
2017-12-21 |
2020-07-29 |
Curevac Ag |
Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
|
|
EP3746090A4
(en)
|
2018-01-29 |
2021-11-17 |
ModernaTX, Inc. |
RSV RNA VACCINES
|
|
EP3773702A2
(en)
|
2018-04-05 |
2021-02-17 |
CureVac AG |
Novel yellow fever nucleic acid molecules for vaccination
|
|
WO2019202035A1
(en)
|
2018-04-17 |
2019-10-24 |
Curevac Ag |
Novel rsv rna molecules and compositions for vaccination
|
|
WO2020002525A1
(en)
|
2018-06-27 |
2020-01-02 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
|
SG11202011097YA
(en)
|
2018-06-28 |
2020-12-30 |
Curevac Ag |
Bioreactor for rna in vitro transcription
|
|
US20220040281A1
(en)
|
2018-12-21 |
2022-02-10 |
Curevac Ag |
Rna for malaria vaccines
|
|
SG11202106666UA
(en)
|
2018-12-21 |
2021-07-29 |
Curevac Ag |
Methods for rna analysis
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
US11241493B2
(en)
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|